SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
|
___________________________________________________ (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of each exchange on which registered | ||
SECTION 8 – Other Events
| Item 8.01 | Other Events |
On September 7, 2021, we issued a press release announcing that we have been selected as a finalist in the 2021 Fierce Pharma Marketing Awards, which honor leadership, vision, innovation and strategic accomplishments within the pharma marketing and advertising arena. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SECTION 9 – Financial Statements and Exhibits
| Item 9.01 | Financial Statements and Exhibits |
| 99.1 | Press release, dated September 7, 2021 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OptimizeRx Corporation
/s/ Douglas Baker
Douglas Baker
Chief Financial Officer
Date: September 7, 2021
2
Exhibit 99.1
OptimizeRx Recognized as a Finalist in Questex’s Fierce Pharma Marketing Awards 2021
OptimizeRx Recognized in the COVID-19 Pandemic-Related Campaign Category
ROCHESTER, Mich. – September 7, 2021 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, announced today that it has been selected as a finalist in the 2021 Fierce Pharma Marketing Awards which honor leadership, vision, innovation and strategic accomplishments within the pharma marketing and advertising arena. OptimizeRx was recognized as a finalist in the category of COVID-19 Pandemic-Related Campaign.
OptimizeRx was selected as a finalist for its COVID-19 Consumer Health Communications Text Message Campaign. The campaign leveraged OptimizeRx’s text-based patient engagement technology, which is traditionally used for specific therapy support programs, to provide the general public with timely COVID-19 information from a reliable source. The free, interactive text-message alert program delivered COVID-19 updates sourced from the Center for Disease Control and Prevention (CDC) directly to any SMS-enabled mobile device.
Fierce Pharma Marketing’s expert panel of judges reviewed all submissions to determine which companies produced thought-provoking, innovative and compelling campaigns across a wide range of media. A full list of judges can be found at https://www.fiercemarketingforum.com/2021%20judges.
The winners will be announced at the Fierce Pharma Marketing Awards Dinner on September 29 at the Pennsylvania Convention Center in Philadelphia, as part of the Digital Pharma East Conference. The event is sponsored by DeepIntent, DrFirst and Doximity.
“It’s been a challenging year for pharma, but it’s also been a creative and innovative one. Pharma marketers and their agencies quickly embraced pandemic-forced changes—moving to digital communications and figuring out how to shoot TV commercials safely, for instance—and continued to produce creative and compelling campaigns all year. We look forward to seeing everybody in Philadelphia in September where we will reveal the winning entries,” commented Tracy Station, Editor-in-Chief, Fierce Pharma. “We applaud OptimizeRx on their success.”
William Febbo, OptimizeRx’s CEO commented, “We are honored to be in such good company in this category and be recognized for our “COVID-19 Consumer Health” campaign. Leveraging OptimizeRx’s best-in-class integrated technology platform for life sciences communications to serve the general public during the height of the pandemic was a testament to the invaluable power of technology in healthcare.
“SMS campaigns are just one of our access solutions that doctors, and life sciences organizations can utilize to facilitate patient engagement outside of the electronic health record in a familiar and convenient manner. It was a no-brainer for our team to leverage the capabilities of the OptimizeRx platform to provide free access to timely and reliable COVID-19 updates, sourced from the CDC. This helped increase accessibility to CDC guidelines on-demand and via automatic notifications so the general public could stay more informed” concluded Mr. Febbo.
OptimizeRx will be present at this year’s Digital Pharma East Conference in Philadelphia at booth number MK1, September 28-30, and at the virtual event, October 5-8.
About Questex
Questex helps people live better and longer. Questex brings people together in the markets that help people live better: travel, hospitality and wellness; the industries that help people live longer: life science and healthcare; and the technologies that enable and fuel these new experiences. We live in the experience economy – connecting our ecosystem through live events, surrounded by data insights and digital communities. We deliver experience and real results. It happens here.
About OptimizeRx
OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.
For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements should not be used to make an investment
decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only
as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties,
some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated
by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include,
but are not limited to, the effect of government regulation, competition and other material risks.
OptimizeRx Contact
Doug Baker, CFO
Tel (248) 651-6568 (x807)
dbaker@optimizerx.com
Media Relations Contact
Maira Alejandra, Media Relations Manager
Tel (754) 245-7070
malejandra@optimizerx.com
Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com
Jennifer Woods
Vice President, Fierce Life Sciences Events
Questex
jwoods@questex.com